Avedro has received CE mark approval for its newest riboflavin formulations, according to a press release.
The new formulations are designed for use in conjunction with Avedro’s KXL system.
The ParaCel formulation for transepithelial cross-linking is based on research and an associated patent by Roberto Pinelli, MD, director of the Istituto Laser Microchirurgia Oculare, the release said.
“ParaCel provides for an easier, faster and more comfortable cross-linking procedure when treating my keratoconic and ectasia patients,” Pinelli said in the release. “When using ParaCel in combination with Avedro’s KXL system, I am able to treat my keratoconic patients in a much shorter time, without the postoperative discomfort associated with removal of the epithelium.”
Avedro is currently sponsoring phase 3 corneal collagen cross-linking trials in the U.S.